Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07376720
What this trial is testing

A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment

Who this might be right for
Multiple Myeloma
Donghua Zhang 28
Early research (Phase 1)Study completedNCT01727778
What this trial is testing

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Drug Safety
Patrys Ltd. 12
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Early research (Phase 1)Study completedNCT05139225
What this trial is testing

TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 7
Not applicableLooking for participantsNCT06515262
What this trial is testing

Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 10
Testing effectiveness (Phase 2)UnknownNCT04714827
What this trial is testing

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanxi Province Cancer Hospital 24
Early research (Phase 1)Study completedNCT01118689
What this trial is testing

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
Millennium Pharmaceuticals, Inc. 39
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Study completedNCT06055075
What this trial is testing

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche 19
Testing effectiveness (Phase 2)Study completedNCT01034553
What this trial is testing

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Mayo Clinic 26
Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Not applicableStudy completedNCT00049465
What this trial is testing

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

Who this might be right for
Cancer
Fred Hutchinson Cancer Center
Not applicableApproved For MarketingNCT02477891
What this trial is testing

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Testing effectiveness (Phase 2)UnknownNCT01435720
What this trial is testing

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMantle Cell Lymphoma in Relapse+3 more
Senesco Technologies, Inc. 15
Early research (Phase 1)Study completedNCT03288480
What this trial is testing

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Promontory Therapeutics Inc. 24
Not applicableApproved For MarketingNCT05757973
What this trial is testing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361
What this trial is testing

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more
Luminary Therapeutics 90
Testing effectiveness (Phase 2)Ended earlyNCT04649073
What this trial is testing

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Otsuka Pharmaceutical Co., Ltd. 11
Testing effectiveness (Phase 2)Looking for participantsNCT07312188
What this trial is testing

F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 90
Next Page